Get started

Compare · CMPI vs EMBCV

CMPI vs EMBCV

Side-by-side comparison of Checkmate Pharmaceuticals Inc. (CMPI) and Embecta Corp. (EMBCV): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CMPI and EMBCV operate in Specialty Chemicals (Consumer Durables), so they compete in similar markets.
  • CMPI has more recent analyst coverage (1 ratings vs 0 for EMBCV).
MetricCMPIEMBCV
Company
Checkmate Pharmaceuticals Inc.
Embecta Corp.
Price
$10.49+0.00%
$33.99-8.00%
Market cap
-
-
1M return
-
-
1Y return
-
-
Sector
Consumer Durables
Consumer Durables
Industry
Specialty Chemicals
Specialty Chemicals
Exchange
NASDAQ
NASDAQ
IPO
2020
News (4w)
0
0
Recent ratings
1
0
CMPI

Checkmate Pharmaceuticals Inc.

Checkmate Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing novel therapeutics for the treatment of cancer. It develops CMP-001, which is in phase II clinical trial in combination with pembrolizumab to treat patients with PD-1 refractory melanoma; combination with nivolumab to treat patients with PD-1 naïve neoadjuvant melanoma; and treatment in patients with PD-1 refractory melanoma. The company has strategic alliances with Merck KGaA and Pfizer. Checkmate Pharmaceuticals, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Latest CMPI

Latest EMBCV